The Quantellect read.As of Nov 19, 2026, 6 active firms cover Monopar Therapeutics Inc: 5 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $100.00 to $145.00, a moderate spread. The average target of $122.83 sits 73% above the current $70.84. The rating mix has stayed broadly stable, with Buy-side ratings easing from 10 to 5 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.31 next quarter toward $-2.98 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 active firms
Buy
Strong Buy00%
Buy583%
Neutral117%
Sell00%
Strong Sell00%
Based on 6 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$122.83
+73.4% upside
Average target across 6 active firms as of Nov 19, 2026 vs $70.84 current
Highest Target$145.00
Average Target$122.83
Lowest Target$100.00
Detailed analyst forecasts for MNPR
Showing 1–6 of 6 named analysts shown · 6 active firms in the rating projection
As of Nov 19, 2026, 5 of 6 active firms rate MNPR a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
MNPR EPS & revenue forecast
EPS · NEXT QUARTER
$-1.31
Range $-2.34 – $-0.34 · 5 analysts · +184% YoY
Next period, 5 analysts expect Monopar Therapeutics Inc to earn $-1.31 a share (range $-2.34 – $-0.34), versus $-0.46 a year earlier. Full-year consensus is $-2.86, growing to $-2.98 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 5 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $27.4M next year.
Top analysts covering Monopar Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MNPR.
#1
Keay Nakae
Chardan Capital · Rank #130
Buy
$100.00+41.2% to target
Overall win rate
41%
+ Follow
#2
Kristen Kluska
Cantor Fitzgerald · Rank #232
Buy
$119.00+68.0% to target
Overall win rate
38%
+ Follow
#3
Joseph Schwartz
Leerink Partners · Rank #242
Buy
$115.00+62.3% to target
Overall win rate
36%
+ Follow
#4
Andres Y. Maldonado
HC Wainwright & Co. · Rank #288
Buy
$125.00+76.5% to target
Overall win rate
39%
+ Follow
#5
Sean Lee
HC Wainwright & Co. · Rank #344
Buy
$40.00-43.5% to target
Overall win rate
40%
+ Follow
MNPR stock forecast FAQ
What is MNPR's average 12-month price target?+
The 6 active firms with a live target average $122.83 for Monopar Therapeutics Inc over the next 12 months, ranging from a $145.00 high to a $100.00 low, as of Nov 19, 2026.
Is MNPR stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 6 active firms as of Nov 19, 2026, 5 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for MNPR?+
The Street-high target is $145.00 (Barclays), and the Street-low is $100.00 (Chardan Capital). The average of all 6 active-firm targets is $122.83.
How many active Wall Street firms cover MNPR?+
6 active firms have a recognized rating on Monopar Therapeutics Inc as of Nov 19, 2026, and 6 active firms carry a live 12-month price target.
Who is the most accurate analyst covering MNPR?+
Among analysts who currently cover MNPR, Keay Nakae of Chardan Capital has the strongest overall Quantellect track record (Rank #130). Their current call is Buy with a $100.00 target.
What is Monopar Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-1.31 per share (range $-2.34 – $-0.34) across 5 analysts. Full-year EPS is projected at $-2.86, rising to $-2.98 the following year.
How much revenue is Monopar Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $27.4M next year.
Have analysts been upgrading or downgrading MNPR lately?+
As of Nov 19, 2026, 5 of 6 active firms rate MNPR a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MNPR calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.